ARX closes out September in an unusual standoff: every analyst on the Street is at Hold or below, yet options traders remain among the most bullishly positioned they have been all year.
The Street's direction of travel has been relentlessly downward since the August 13 earnings print. TD Cowen's Andrew Kligerman delivered the latest blow on September 30, cutting to Hold and slashing his price target from $30.00 to $20.25, a 32.5% reduction. That is the fourth downgrade in six weeks. Raymond James moved to Underperform on September 23. Citizens and William Blair both stepped down from outperform-equivalent ratings immediately after the August result. The consensus now sits at a clean Hold, with five analysts covering and zero buys. The mean target of $20.25 sits barely above yesterday's close of $19.73, offering almost no implied upside on the Street's current view. The bear case has not changed: third-party premium mix falling to 54% from 58%, net investment income down 24.7%, and guidance that left the Street cold. The August revenue print of $267.4 million, up 74% year on year, has not been enough to hold analyst conviction.
Options traders have drawn a very different conclusion. The put/call ratio has collapsed to 0.38, roughly 1.3 standard deviations below its 20-day average of 0.54. That is close to the most call-heavy positioning ARX has seen over the past year, against a 52-week PCR low of 0.08 and high of 1.21. The shift is recent and sharp. Through most of September the PCR ran near 0.63; it dropped abruptly around September 22 and has held in a tight range since. The divergence between an all-Hold analyst consensus and call-heavy options positioning is the defining tension in ARX right now.
Short interest is falling, which is consistent with neither a crowded bear trade nor a squeeze setup. SI has dropped 13.5% over the past week and 26% over the past month, now running at 4.0% of free float. Borrow availability is exceptionally loose at roughly 29 times the current short interest, so there is no friction discouraging new shorts from entering if they choose to. The one wrinkle in the lending picture is cost to borrow, which jumped sharply on September 29 to 2.06%, up from 0.63% the day before and from a range of 0.36% to 0.76% across the prior six weeks. A single-day CTB spike on falling short interest is worth watching, though it may reflect settlement or end-of-month mechanics rather than a sustained change in borrow demand. The ORTEX short score has also eased, dropping from around 45 in mid-September to 40.3 now, consistent with the direction in short interest.
Insider activity in the 90-day window shows net selling of roughly 1.57 million shares, worth approximately $20.9 million. The CEO and co-founder Jeffrey Radke and co-founder and Chief Underwriting Officer Francis O'Neill were both active sellers through July and August, predominantly under pre-arranged 10b5-1 plans. Plan-based sales are compensation mechanics rather than discretionary signals, but the scale and timing, immediately following the post-earnings stock surge of over 43%, is worth noting. Glazer Capital filed a fresh Schedule 13G on September 30, disclosing a 5.0% passive stake of roughly 5.97 million shares. No 13D activists are on the register. Stakes are as last disclosed and holders who drop below 5% may not file again.
The EPS surprise factor score ranks in the 93rd percentile and the 90-day EPS momentum score is at the 87th percentile, both of which reflect the August beat rather than any forward view. The EV/EBIT factor score, however, sits at just the 5th percentile, flagging that valuation is not cheap on an earnings-adjusted basis despite the stock trading essentially flat on the month. The next earnings event is scheduled for November 13, and with the analyst consensus at dead centre Hold and no buy ratings on the sheet, that print will be the clearest test of whether the August growth rate can hold.
See the live data behind this article on ORTEX.
Open ARX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
